Navigation Links
Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
Date:5/25/2012

CRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its new Scientific Advisory Board, which will be headed by Joseph Bertino, M.D., currently Chief Scientific Officer and Associate Director of the Cancer Institute of New Jersey at UMDNJ-Robert Wood Johnson Medical School.

"Oncobiologics is fortunate to add pros like Steve and Vince to our management team. Their interest in Oncobiologics is an indication that our existing team and recent technical progress continue to attract the best and the brightest from the industry," said Oncobiologics Founder & CEO Pankaj Mohan, Ph.D. 

Mohan continued, "In addition, the establishment of our Scientific Advisory Board with Dr. Bertino at the helm is a watershed moment for Oncobiologics. This external group of experts will provide critical clinical and strategic direction to guide the progress of our novel biotherapeutics." 

Dr. McAndrew is responsible for the company's revenue growth strategy and initiatives, establishing and managing all collaborative research and commercial product partnerships, and sourcing selected investment opportunities. Prior to joining Oncobiologics, Dr. McAndrew served as Vice President, Business Development for Xenogen Biosciences, Caliper Life Sciences and Taconic Biosciences. Previously, he served as Vice President, Pharmaceutical Business Development for Lexicon Pharmaceuticals and Director, Biotechnology Licensing for Bristol-Myers Squibb Company. Earlier, Dr. McAndrew led applied research programs within Discovery-Oncology at Bristol-Myers Squibb, and exploratory research in the Roche Institute of Molecular Biology at Hoffmann La-Roche.

Dr. Benn is responsible for Oncobiologics' clinical programs, regulatory strategies and regulatory affairs. He brings more than 30 years of clinical and regulatory drug and biologics development experience to Oncobiologics. Previously, he was Vice President Clinical & Regulatory Affairs at Essential Pharmaceuticals, Vice President Worldwide Clinical Operations at Discovery Labs, and Global Clinical Program Director at Aventis Behring LLC. He brings extensive experience in the development and defense of clinical development plans before FDA, EMEA, MCA, MPA, and the Paul Erlich Institute (PEI).

In addition to Dr. Bertino, Scientific Advisory Board members include Debabrata Banerjee, Ph.D., Associate Professor of Medicine & Pharmacology at Robert Wood Johnson Medical School & Adjunct Associate Prof at New York Medical College; Igor A. Astsaturov, M.D., Ph.D., Assistant Professor and Attending Oncologist at Fox Chase Cancer Center in Philadelphia; Hossein Borghaei, D.O., M.S., Director of Thoracic Medical Oncology and Co-Leader, Thoracic Cancer Service at Fox Chase Cancer Center; Matt Robinson, Ph.D., Assistant Professor in the Developmental Therapeutics Program at Fox Chase Cancer Center; Mak Jawadekar, Ph.D., formerly Director, Portfolio Management & Analytics, Pfizer, Inc. and Vice President of Asia CRG at Pfizer Inc.; and Mauricio Futran, Ph.D., Professor and Chair of Chemical and Biochemical Engineering at Rutgers University, with nearly 30 years of experience at Merck & Co. and Bristol-Myers Squibb.

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of next-generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. The company's proprietary TRIDENT™ platform leverages fully human single-chain, bi-specific antibodies with HSA binding designed for overall significantly enhanced efficacy, safety, and pharmacokinetics with targeted delivery. For more information, please visit www.oncobiologics.com or call 609-619-3990.

Contact:

Rick Gregory
R.C. Gregory & Co.
860-677-2377
rick@rcgregory.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
2. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
3. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
4. Sanford Rose Associates® - Minneapolis Fills Key Management Position for the Micromedics Operation of Nordson Corporation
5. RBC Life Sciences Fills Newly Created Vice President of Sales and Marketing Position With Industry Veteran
6. New Pleio Medication Adherence Service Increases Prescription Refills Up To 53%
7. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
8. USC Marshall School of Business 6th Annual Leadership Summit
9. More than half of Americans doubt US global leadership in 2020
10. Auxilium Announces Appointments to Enhance Leadership Team
11. Berkeley Lab seeks to help US assert scientific leadership in critical materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... ... , ... FireflySci, Inc is an explosive small business that continues to grow ... bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy world. ... on as they add yet another mark on the global map. , With distributors ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):